AR109180A1 - Derivados de piperidina como moduladores del receptor cxcl11 / cxcl12 cxcr7 - Google Patents
Derivados de piperidina como moduladores del receptor cxcl11 / cxcl12 cxcr7Info
- Publication number
- AR109180A1 AR109180A1 ARP170102126A ARP170102126A AR109180A1 AR 109180 A1 AR109180 A1 AR 109180A1 AR P170102126 A ARP170102126 A AR P170102126A AR P170102126 A ARP170102126 A AR P170102126A AR 109180 A1 AR109180 A1 AR 109180A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluoroalkyl
- alkoxy
- independently
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Abstract
Productos farmacéuticos, a composiciones farmacéuticas que contienen uno o varios compuestos reivindicados y en especial a su uso como moduladores del receptor CXCR7. Reivindicación 1: Un compuesto de la fórmula (1), en donde los dos sustituyentes del anillo piperidina: R¹-CO- y -NH-CO-Ar¹-Ar², están en configuración trans relativa; Ar¹ representa un grupo heteroarileno de 5 miembros, en donde el grupo -NH-CO- y Ar² se unen en disposición meta con átomos de anillo de Ar¹; en donde dicho heteroarileno de 5 miembros no está sustituido o está monosustituido con RAʳ¹; en donde RAʳ¹ representa alquilo C₁₋₄, alcoxi C₁₋₄, halógeno, fluoroalquilo C₁₋₃ o fluoroalcoxi C₁₋₃; Ar² representa fenilo o heteroarilo de 6 miembros; en donde dicho fenilo o heteroarilo de 6 miembros está, de modo independiente, mono-, di- o trisustituido, en donde los sustituyentes están seleccionados, de modo independiente, de fluoro, cloro, metilo, ciano, metoxi o fluoroalquilo C₁; R¹ representa RN¹RN²N-, en donde RN¹ representa hidrógeno; alquilo C₁₋₆; alquilo C₁₋₆ que está monosustituido con hidroxi; alcoxi C₁₋₃; 2-hidroxi-etoxi; -CO-NH₂; -SO₂-alquilo C₁₋₃; ciano; fluoroalcoxi C₁₋₃; -NRN³RN⁴, en donde RN³ y RN⁴ representan, de modo independiente, hidrógeno o alquilo C₁₋₄; alquinilo C₂₋₆; fluoroalquilo C₂₋₅; alcoxi C₁₋₄; 2-(2-oxo-pirrolidin-1-il)-etilo; un grupo -L¹-Cy¹; en donde L¹ representa un enlace directo, -alquileno C₁₋₃- o -cicloalquileno C₃₋₅-; y Cy¹ representa cicloalquilo C₃₋₆, en donde dicho cicloalquilo C₃₋₆ opcionalmente contiene un átomo de oxígeno del anillo; en donde dicho cicloalquilo C₃₋₆ de modo independiente no está sustituido; o monosustituido con fluoro, metilo o hidroxi, -CO-alcoxi C₁₋₄ o ciano; o disustituido con fluoro o trisustituido con metilo y dos fluoro; un grupo -L²-Ar³, en donde L² representa un enlace directo, -alquileno C₁₋₄-; *-cicloalquileno C₃₋₅-alquileno C₀₋₂- en donde dicho cicloalquileno C₃₋₅ opcionalmente contiene un átomo de oxígeno del anillo, en donde el asterisco indica el enlace con el que Ar³ está unido; *-alquilen C₁₋₂-cicloalquileno C₃₋₅- en donde dicho cicloalquileno C₃₋₅ opcionalmente contiene un átomo de oxígeno del anillo, en donde el asterisco indica el enlace con el que Ar³ está unido; o -alquileno C₁₋₃- que está monosustituido con hidroxi, trifluorometilo o -CO-alcoxi C₁₋₄; y Ar³ representa fenilo o heteroarilo de 5 ó 6 miembros; en donde dicho fenilo o heteroarilo de 5 ó 6 miembros de modo independiente no está sustituido o mono- o disustituido; en donde los sustituyentes están seleccionados, de modo independiente, de alquilo C₁₋₄, alcoxi C₁₋₄, halógeno, hidroxi, fluoroalquilo C₁₋₃ o fluoroalcoxi C₁₋₃; en donde, en caso de que Ar³ representa heteroarilo de 6 miembros que es piridilo o pirimidinilo, tal piridilo o pirimidinilo puede estar presente adicionalmente en forma del N-óxido respectivo; y RN² representa, de modo independiente, hidrógeno, alquilo C₁₋₄ o fluoroalquilo C₂₋₃; o RN¹ y RN² junto con el átomo de nitrógeno al que están unidos forman un anillo de 4 a 6 miembros seleccionado de azetidinilo, pirrolidinilo o piperidinilo; cada uno, de modo independiente, no sustituido; o monosustituido con fluoro, metilo o hidroxi; o disustituido con fluoro; o monosustituido con Ar⁴, en donde Ar⁴ representa fenilo o heteroarilo de 5 ó 6 miembros; en donde dicho fenilo o heteroarilo de 5 ó 6 miembros de modo independiente no está sustituido o mono- o disustituido; en donde los sustituyentes están seleccionados, de modo independiente, de alquilo C₁₋₄, alcoxi C₁₋₄, halógeno, fluoroalquilo C₁₋₃ o fluoroalcoxi C₁₋₃; o morfolinilo; R² representa hidrógeno; alquilo C₁₋₆; o alquilo C₂₋₆ que está monosustituido con alcoxi C₁₋₃ o hidroxi; alquenilo C₃₋₅ (en especial alilo); ciano-metilo; fluoroalquilo C₂₋₃; cicloalquil C₃₋₈-alquilo C₀₋₃; en donde el cicloalquilo C₃₋₈ no está sustituido o está mono- o disustituido en donde los sustituyentes están seleccionados, de modo independiente, de alquilo C₁₋₃, fluoro, hidroxi, hidroxi-alquilo C₁₋₃, alcoxi C₁₋₃ o fluoroalquilo C₁₋₃; tietan-3-ilo; cicloalquenil C₃₋₈-alquilo C₁₋₃; o Ar⁵-CH₂- en donde Ar⁵ representa fenilo o heteroarilo de 5 ó 6 miembros, en donde el fenilo o heteroarilo de 5 ó 6 miembros de modo independiente no está sustituido o está mono- o disustituido en donde los sustituyentes están seleccionados, de modo independiente, de alquilo C₁₋₄, alcoxi C₁₋₄, halógeno, fluoroalquilo C₁₋₃ o fluoroalcoxi C₁₋₃; y R³ representa hidrógeno o metilo; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016068052 | 2016-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109180A1 true AR109180A1 (es) | 2018-11-07 |
Family
ID=59656027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102126A AR109180A1 (es) | 2016-07-28 | 2017-07-27 | Derivados de piperidina como moduladores del receptor cxcl11 / cxcl12 cxcr7 |
| ARP190101842A AR115662A2 (es) | 2016-07-28 | 2019-07-01 | Derivados de piperidina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101842A AR115662A2 (es) | 2016-07-28 | 2019-07-01 | Derivados de piperidina |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10752620B2 (es) |
| EP (2) | EP3490986B1 (es) |
| JP (2) | JP6655754B2 (es) |
| KR (2) | KR102497095B1 (es) |
| CN (2) | CN109563085B (es) |
| AR (2) | AR109180A1 (es) |
| AU (2) | AU2017302079B2 (es) |
| BR (1) | BR112019001551A2 (es) |
| CA (1) | CA3032017C (es) |
| CL (2) | CL2019000169A1 (es) |
| CY (1) | CY1125016T1 (es) |
| DK (2) | DK3798217T3 (es) |
| EA (2) | EA037507B1 (es) |
| ES (2) | ES2905755T3 (es) |
| FI (1) | FI3798217T3 (es) |
| HR (2) | HRP20230313T1 (es) |
| HU (2) | HUE062019T2 (es) |
| IL (2) | IL264424B (es) |
| LT (2) | LT3490986T (es) |
| MA (2) | MA45782B1 (es) |
| MX (2) | MX2019001042A (es) |
| MY (1) | MY198113A (es) |
| NZ (1) | NZ751006A (es) |
| PH (1) | PH12019500188A1 (es) |
| PL (2) | PL3490986T3 (es) |
| PT (2) | PT3798217T (es) |
| RS (2) | RS64130B1 (es) |
| SG (2) | SG11201900633XA (es) |
| SI (2) | SI3490986T1 (es) |
| TW (3) | TWI683812B (es) |
| WO (1) | WO2018019929A1 (es) |
| ZA (1) | ZA201901256B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11339148B2 (en) * | 2018-01-26 | 2022-05-24 | Idorsia Pharmaceuticals Ltd. | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
| IL292529A (en) | 2019-10-31 | 2022-06-01 | Idorsia Pharmaceuticals Ltd | Combination of cxcr7 antagonist with s1p1 receptor modulator |
| CA3226468A1 (en) | 2021-08-02 | 2023-02-09 | Andrew Edmunds | Microbiocidal pyrazole derivatives |
| CN117396471A (zh) * | 2021-10-01 | 2024-01-12 | 株式会社次代生物科学 | 新的哌啶衍生物和包含其的用于抑制自分泌运动因子的药物组合物 |
| WO2023110871A1 (en) | 2021-12-17 | 2023-06-22 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| EP4238970A1 (en) | 2022-03-03 | 2023-09-06 | InterAx Biotech AG | Modulators of ackr3 and uses thereof |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102324A1 (en) * | 2002-02-28 | 2004-05-27 | Annis Gary David | Heterocyclic diamide invertebrate pest control agents |
| MXPA05005660A (es) | 2002-11-27 | 2005-10-18 | Incyte Corp | Derivados de 3-aminopirrolidina como moduladores de receptores de quimocina. |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| US7115646B2 (en) | 2003-10-08 | 2006-10-03 | Bristol Myers Squibb, Co. | Cyclic diamines and derivatives as factor Xa inhibitors |
| UA94901C2 (ru) | 2005-02-18 | 2011-06-25 | Астразенека Аб | Антибактериальные производные пиперидина |
| US8288373B2 (en) * | 2008-11-04 | 2012-10-16 | Chemocentryx, Inc. | Modulators of CXCR7 |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン |
| WO2013084241A1 (en) * | 2011-12-09 | 2013-06-13 | Cadila Healthcare Limited | Compounds as inhibitors of renin |
| AR091516A1 (es) | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| AU2013352304C1 (en) * | 2012-11-29 | 2018-03-22 | Chemocentryx, Inc. | CXCR7 antagonists |
| EP3004082B1 (en) * | 2013-05-30 | 2017-08-02 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
| CA2923184A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| PL3363790T3 (pl) | 2013-09-06 | 2020-07-27 | Aurigene Discovery Technologies Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| MX2017002986A (es) * | 2014-09-10 | 2017-10-24 | Epizyme Inc | Compuestos de piperidina sustituidos. |
| EP3227263B1 (en) | 2014-12-01 | 2019-04-10 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
| US11339148B2 (en) | 2018-01-26 | 2022-05-24 | Idorsia Pharmaceuticals Ltd. | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
-
2017
- 2017-07-27 SG SG11201900633XA patent/SG11201900633XA/en unknown
- 2017-07-27 HU HUE20201796A patent/HUE062019T2/hu unknown
- 2017-07-27 LT LTEPPCT/EP2017/068990T patent/LT3490986T/lt unknown
- 2017-07-27 NZ NZ751006A patent/NZ751006A/en unknown
- 2017-07-27 CA CA3032017A patent/CA3032017C/en active Active
- 2017-07-27 MA MA45782A patent/MA45782B1/fr unknown
- 2017-07-27 SI SI201731053T patent/SI3490986T1/sl unknown
- 2017-07-27 CN CN201780046279.9A patent/CN109563085B/zh active Active
- 2017-07-27 EA EA201990388A patent/EA037507B1/ru not_active IP Right Cessation
- 2017-07-27 ES ES17754283T patent/ES2905755T3/es active Active
- 2017-07-27 LT LTEP20201796.8T patent/LT3798217T/lt unknown
- 2017-07-27 WO PCT/EP2017/068990 patent/WO2018019929A1/en active Application Filing
- 2017-07-27 SI SI201731333T patent/SI3798217T1/sl unknown
- 2017-07-27 PL PL17754283T patent/PL3490986T3/pl unknown
- 2017-07-27 EP EP17754283.4A patent/EP3490986B1/en active Active
- 2017-07-27 KR KR1020207021496A patent/KR102497095B1/ko active IP Right Grant
- 2017-07-27 DK DK20201796.8T patent/DK3798217T3/da active
- 2017-07-27 MA MA54653A patent/MA54653B1/fr unknown
- 2017-07-27 FI FIEP20201796.8T patent/FI3798217T3/fi active
- 2017-07-27 ES ES20201796T patent/ES2954152T3/es active Active
- 2017-07-27 PT PT202017968T patent/PT3798217T/pt unknown
- 2017-07-27 TW TW106125273A patent/TWI683812B/zh active
- 2017-07-27 MY MYPI2019000420A patent/MY198113A/en unknown
- 2017-07-27 HR HRP20230313TT patent/HRP20230313T1/hr unknown
- 2017-07-27 JP JP2019503918A patent/JP6655754B2/ja active Active
- 2017-07-27 SG SG10201906942PA patent/SG10201906942PA/en unknown
- 2017-07-27 HR HRP20211988TT patent/HRP20211988T1/hr unknown
- 2017-07-27 TW TW108111240A patent/TWI691497B/zh active
- 2017-07-27 AR ARP170102126A patent/AR109180A1/es unknown
- 2017-07-27 RS RS20230297A patent/RS64130B1/sr unknown
- 2017-07-27 RS RS20220082A patent/RS62855B1/sr unknown
- 2017-07-27 PL PL20201796.8T patent/PL3798217T3/pl unknown
- 2017-07-27 MX MX2019001042A patent/MX2019001042A/es unknown
- 2017-07-27 KR KR1020197005980A patent/KR102497091B1/ko active IP Right Grant
- 2017-07-27 EP EP20201796.8A patent/EP3798217B1/en active Active
- 2017-07-27 CN CN201910748606.6A patent/CN110563717B/zh active Active
- 2017-07-27 BR BR112019001551-5A patent/BR112019001551A2/pt active Search and Examination
- 2017-07-27 PT PT177542834T patent/PT3490986T/pt unknown
- 2017-07-27 HU HUE17754283A patent/HUE057315T2/hu unknown
- 2017-07-27 DK DK17754283.4T patent/DK3490986T3/da active
- 2017-07-27 TW TW108111236A patent/TWI691494B/zh active
- 2017-07-27 AU AU2017302079A patent/AU2017302079B2/en active Active
- 2017-07-27 US US16/320,906 patent/US10752620B2/en active Active
- 2017-07-27 EA EA202091262A patent/EA202091262A1/ru unknown
-
2019
- 2019-01-22 CL CL2019000169A patent/CL2019000169A1/es unknown
- 2019-01-23 IL IL264424A patent/IL264424B/en unknown
- 2019-01-24 MX MX2021004000A patent/MX2021004000A/es unknown
- 2019-01-25 PH PH12019500188A patent/PH12019500188A1/en unknown
- 2019-02-27 ZA ZA2019/01256A patent/ZA201901256B/en unknown
- 2019-03-15 JP JP2019048980A patent/JP6655742B2/ja active Active
- 2019-07-01 AR ARP190101842A patent/AR115662A2/es unknown
- 2019-11-15 CL CL2019003281A patent/CL2019003281A1/es unknown
-
2020
- 2020-07-09 AU AU2020204578A patent/AU2020204578B2/en active Active
- 2020-07-14 US US16/928,787 patent/US11306078B2/en active Active
-
2021
- 2021-05-05 IL IL282942A patent/IL282942B/en unknown
-
2022
- 2022-02-21 CY CY20221100143T patent/CY1125016T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109180A1 (es) | Derivados de piperidina como moduladores del receptor cxcl11 / cxcl12 cxcr7 | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| ES2659397T3 (es) | 2-azabicíclicos sustituidos y su uso como moduladores receptores de orexinas | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR091962A1 (es) | Compuesto antidiabeticos triciclicos | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR088565A1 (es) | Inhibidor de cetp de oxazolidinona biciclico fusionado | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR095508A1 (es) | 4-amino-6-(heterocíclico)picolinatos y 6-amino-2-(heterocíclico)pirimidina-4-carboxilatos y su uso como herbicidas | |
| ES2721031T3 (es) | Compuestos de dihidroisoquinolinona sustituidos | |
| AR100712A1 (es) | Compuestos de pirazol como bloqueadores de los canales de calcio tipo t | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR103414A1 (es) | Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3 | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| ES2682398T3 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR111874A1 (es) | Derivados de pirimidina | |
| AR098723A1 (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
| AR104672A1 (es) | Inhibidores de grelina o-aciltransferasa | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| EA201270111A1 (ru) | Новые производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования акт(ркв) | |
| AR094797A1 (es) | Derivados de pirrolotriazina como inhibidores de pi3k |